Zacks Research Has Negative Forecast for GSK Q1 Earnings

GSK plc (NYSE:GSK) – Stock analysts at Zacks Research dropped their Q1 2025 earnings estimates for shares of GSK in a research note issued on Wednesday, December 11th. Zacks Research analyst E. Bagri now expects that the pharmaceutical company will post earnings of $1.10 per share for the quarter, down from their prior forecast of $1.11. The consensus estimate for GSK’s current full-year earnings is $4.02 per share. Zacks Research also issued estimates for GSK’s Q3 2025 earnings at $1.33 EPS, Q4 2025 earnings at $0.79 EPS, FY2025 earnings at $4.24 EPS and FY2026 earnings at $4.73 EPS.

GSK has been the subject of several other research reports. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Barclays raised shares of GSK to a “hold” rating in a report on Tuesday, August 27th. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and cut their price target for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Thursday. Seven investment analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the stock. According to MarketBeat, GSK currently has an average rating of “Moderate Buy” and an average price target of $43.25.

GSK Price Performance

GSK stock opened at $33.95 on Friday. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. GSK has a one year low of $32.83 and a one year high of $45.92. The firm has a market capitalization of $70.36 billion, a P/E ratio of 22.05, a PEG ratio of 1.54 and a beta of 0.64. The business has a fifty day moving average price of $36.18 and a 200-day moving average price of $39.25.

Institutional Investors Weigh In On GSK

A number of institutional investors have recently made changes to their positions in the business. Wealth Enhancement Advisory Services LLC boosted its holdings in GSK by 5.7% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 166,255 shares of the pharmaceutical company’s stock valued at $6,401,000 after acquiring an additional 8,989 shares during the period. ORG Partners LLC grew its holdings in shares of GSK by 663.5% in the second quarter. ORG Partners LLC now owns 1,611 shares of the pharmaceutical company’s stock worth $62,000 after purchasing an additional 1,400 shares during the last quarter. Triad Wealth Partners LLC purchased a new position in shares of GSK in the second quarter worth $49,000. Blue Trust Inc. raised its holdings in GSK by 168.4% during the 2nd quarter. Blue Trust Inc. now owns 2,464 shares of the pharmaceutical company’s stock valued at $95,000 after buying an additional 1,546 shares during the last quarter. Finally, NORTHSTAR ASSET MANAGEMENT Co LLC boosted its position in GSK by 13.8% during the 2nd quarter. NORTHSTAR ASSET MANAGEMENT Co LLC now owns 6,005 shares of the pharmaceutical company’s stock valued at $231,000 after buying an additional 728 shares during the period. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Insider Buying and Selling

In other GSK news, major shareholder Plc Gsk purchased 2,791,930 shares of the firm’s stock in a transaction on Friday, September 27th. The shares were purchased at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the purchase, the insider now owns 16,775,691 shares of the company’s stock, valued at $134,205,528. The trade was a 19.97 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 10.00% of the stock is owned by company insiders.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be issued a dividend of $0.3928 per share. This is an increase from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.63%. The ex-dividend date of this dividend is Friday, November 15th. GSK’s payout ratio is currently 99.35%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.